CINV: still troubling patients after all these years

被引：88

作者：

Aapro, Matti ^{[1
]}

机构：

[1] Clin Genolier, Ctr Canc, Route Muids 3,POB 100, CH-1272 Genolier, Switzerland

来源：

SUPPORTIVE CARE IN CANCER | 2018年 / 26卷

关键词：

Chemotherapy-induced nausea and vomiting; CINV; NK-1 receptor antagonist; 5-HT3 receptor antagonist; Anticipatory CINV; Breakthrough CINV; CHEMOTHERAPY-INDUCED NAUSEA; EUROPEAN EMESIS REGISTRY; CANCER-PATIENTS; EMETOGENIC CHEMOTHERAPY; RECEPTOR ANTAGONISTS; GUIDELINE UPDATE; PREVENTION; ANTIEMETICS; ROLAPITANT; 5-HT3;

D O I：

10.1007/s00520-018-4131-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. The emergence of receptor antagonists targeting serotonin and neurokinin-1 have revolutionized the prevention of CINV, significantly reducing the impact of this side effect and improving patient quality of life. However, several areas of unmet need remain, including adequate prevention of nausea, rather than just vomiting, in patients receiving chemotherapy for cancer. Prevention of delayed CINV and anticipatory CINV, as well as management of breakthrough CINV, also continues to challenge patients and clinicians. Ongoing research continues to address these areas to improve antiemetic therapies and guidelines.

引用

页码：S5 / S9

页数：5

共 26 条

[1] The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) [J].

Aapro, M. ;

Molassiotis, A. ;

Dicato, M. ;

Pelaez, I. ;

Rodriguez-Lescure, A. ;

Pastorelli, D. ;

Ma, L. ;

Burke, T. ;

Gu, A. ;

Gascon, P. ;

Roila, F. .

ANNALS OF ONCOLOGY, 2012, 23 (08) :1986-1992

[2]

[Anonymous], 1997, Oncology (Williston Park), V11, P57

[3]

[Anonymous], 2017, NCCN clinical practice guidelines in oncology: Survivorship

[4] Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles [J].

Bayo, Juan ;

Fonseca, Paula J. ;

Hernando, Susana ;

Servitja, Sonia ;

Calvo, Aitana ;

Falagan, Sandra ;

Garcia, Estefania ;

Gonzalez, Iria ;

Jose de Miguel, Maria ;

Perez, Quionia ;

Milena, Ana ;

Ruiz, Antonio ;

Barnadas, Agusti .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (06) :413-422

[5] Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence [J].

Chasen, Martin R. ;

Rapoport, Bernardo L. .

FUTURE ONCOLOGY, 2016, 12 (06) :763-778

[6] Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials [J].

Di Maio, Massimo ;

Gallo, Ciro ;

Leighl, Natasha B. ;

Piccirillo, Maria Carmela ;

Daniele, Gennaro ;

Nuzzo, Francesco ;

Gridelli, Cesare ;

Gebbia, Vittorio ;

Ciardiello, Fortunato ;

De Placido, Sabino ;

Ceribelli, Anna ;

Favaretto, Adolfo G. ;

de Matteis, Andrea ;

Feld, Ronald ;

Butts, Charles ;

Bryce, Jane ;

Signoriello, Simona ;

Morabito, Alessandro ;

Rocco, Gaetano ;

Perrone, Francesco .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) :910-+

[7] The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting [J].

Dranitsaris, G. ;

Molassiotis, A. ;

Clemons, M. ;

Roeland, E. ;

Schwartzberg, L. ;

Dielenseger, P. ;

Jordan, K. ;

Young, A. ;

Aapro, M. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1260-1267

[8] 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting [J].

Einhorn, Lawrence H. ;

Rapoport, Bernardo ;

Navari, Rudolph M. ;

Herrstedt, Jorn ;

Brames, Mary J. .

SUPPORTIVE CARE IN CANCER, 2017, 25 (01) :303-308

[9] Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [J].

Escobar, Yolanda ;

Cajaraville, Gerardo ;

Antonio Virizuela, Juan ;

Alvarez, Rosa ;

Munoz, Andres ;

Olariaga, Olatz ;

Jose Tames, Maria ;

Muros, Begona ;

Jose Lecumberri, Maria ;

Feliu, Jaime ;

Martinez, Purificacion ;

Carlos Adansa, Juan ;

Jose Martinez, Maria ;

Lopez, Rafael ;

Blasco, Ana ;

Gascon, Pere ;

Calvo, Virginia ;

Luna, Pablo ;

Montalar, Joaquin ;

Del Barrio, Patricia ;

Victoria Tornamira, Maria .

SUPPORTIVE CARE IN CANCER, 2015, 23 (09) :2833-2840

[10] Rolapitant for the Prevention of Postoperative Nausea and Vomiting: A Prospective, Double-Blinded, Placebo-Controlled Randomized Trial [J].

Gan, Tong J. ;

Gu, Jiezhun ;

Singla, Neil ;

Chung, Frances ;

Pearman, Michael H. ;

Bergese, Sergio D. ;

Habib, Ashraf S. ;

Candiotti, Keith A. ;

Mo, Yi ;

Huyck, Susan ;

Creed, Mary R. ;

Cantillon, Marc .

ANESTHESIA AND ANALGESIA, 2011, 112 (04) :804-812

← 1 2 3 →